Skip to main content

VERV

Stock

VERV

Stock
Health Care
Biotechnology

Performance overview

VERV Price
Price Chart

Forward-looking statistics

Beta
1.39
Risk
91.97%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.

Company info

SectorHealth Care
IndustryBiotechnology
Employees243
Market cap$437.5M

Fundamentals

Enterprise value$572.6M
Revenue$59.6M
Revenue per employee—
Profit margin0.00%
Debt to equity14.49

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.11
Dividend per share—
Revenue per share$0.69
Avg trading volume (30 day)$71M
Avg trading volume (10 day)$44M
Put-call ratio—

Macro factor sensitivity

Growth+0.9
Credit+7.3
Liquidity-1.2
Inflation-1.7
Commodities+1.5
Interest Rates-4.2

Valuation

Dividend yield0.00%
PEG Ratio-3.90
Price to sales16.90
P/E Ratio-3.90
Enterprise Value to Revenue9.61
Price to book2.12

Upcoming events

Next earnings dayMay 8, 2024
Next dividend day—
Ex. dividend day—

News

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

Zacks Investment Research (June 18, 2025)
Lilly to buy gene-editing partner Verve for $1.3 billion

CNBC's Angelica Peebles reports on the latest news surrounding Eli Lilly.

CNBC Television (June 17, 2025)
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga (June 17, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free